Swedencare Ab · OMXSTO:SECARE
Swedencare Ab — Q3 2026 Earnings Presentation
19 slides from Swedencare Ab's earnings presentation, Oct 21, 2026
Slide 1: Q3 Report
Q3 Report PRESENTATION WILL BEGIN SHORTLY
Slide 2: Q3 Report July - September 2026
Q3 Report JULY - SEPTEMBER 2026 with Håkan Lagerberg, CEO Jenny Graflind, CFO
Slide 3: Strong momentum in Europe and Production, North America turnaround in progress
Strong momentum in Europe and Production, North America turnaround in progress Group +3% I Organic +2% I Q2-Q3 +9% I Europe +11% I Production +11% I North America -4% Dental, Pharma and Production driving growth Amazon & Export continue strong momentum Summit soft chews launched CEO transition annou
Slide 4: Financial Highlights Q3 2026
Financial Highlights Q3 2026 Comments Net Revenue Organic Growth 700 +3% • Q: Org +2%, +1% acq, 0% Fx 600 14% • YTD: 6% organic growth 500 12% • Gross Margin 59,2% 400 10% • Improved, stabile and as 300 8% -87% expected 6% • OpEx 200 • Strong Amazon growth 4% 100 • Personal costs in line with LY 2%
Slide 5: Financial Highlights Q3 2026
Financial Highlights Q3 2026 Comments Net Debt/EBITDA • Decrease of 0,1 since last Q • Expected EO for Summit included Net Debt / EBITDA from Q2 Op. cash flow / Cash conversion Cash 3,0 +12% 140 • Positive trend since Q4 2,5 120 -37% • Continued inventory build-up • CapEx 3% 2,0 100 • Investment in
Slide 6: Rolling 4 quarters
Rolling 4 quarters Rolling twelve months - net revenue and EBITDA 3000 600 800 160 700 140 2500 500 600 120 2000 400 500 100 1500 300 400 80 300 60 1000 200 200 40 500 100 100 20 0 0 0 0 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 R12 2026 Q3 2021 Q3 2022 Q3 2023 Q3 2024 Q3 2025 Q3 2026* *During Q3 2026
Slide 7: North America – Turnaround actions gaining traction
North America –Turnaround actions gaining traction 56% Net sales 406 MSEK I Organic growth -4% of total net revenue • NaturVet retail stabilizing; positive POS trend, 400 -4% comps impacted by WM launch Q3 LY 300 • Online soft growth, expected to accelerate in 200 Q4 100 • ProDen PlaqueOff® continue
Slide 8: Europe – Double digit growth led by Online
Europe – Double digit growth led by Online 25% Net Sales 184 MSEK I +13% Y-Y I Organic 11% of total net revenue 180 +13% • Strong growth across most European businesses 150 120 • Online driving growth, led by the UK 90 60 • UK retail expansion with NaturVet and 30 ProDen PlaqueOff® 0 Q2 Q3 Q4 Q1 Q2
Slide 9: Production – Double digit growth with further upside
Production – Double digit growth with further upside 19% Net sales 142 MSEK I Organic growth +11% of total net revenue • Strong growth in UK, Ireland & Pharma 140 120 +11% • US Dermatology remains the key drag 100 • Strong pipeline with new and existing 80 60 customers 40 • SQF certification passed
Slide 10: Four priorities to accelerate growth and profitability
Four priorities to accelerate growth and profitability 1. Turn North America 2. Improve operational around efficiency Return to segment growth Production, Supply chain & growth & delivery 3. Accelarate Online & D2C 4. Leverage our global platform Drive growth, loyalty & higher margin sales More cros
Slide 11: Production Highlights
Production Highlights John Kane, Q3 2026 Conference Call The Production Segment continues to invest in new manufacturing capabilities across numerous sectors of the Animal Health industry
Slide 12: Outline
Outline Pharma Segment Growth Summit Vet performance + Vetio North drug development pipeline generating growth and opportunities Summit Vet Soft Chew Launch Leveraging Vetio’s global intellectual property to launch the industry’s first soft chew specials in the UK Vetio South Expansion Facility expa
Slide 13: Pharma Segment
Pharma Segment • Montreal, Canada • Oxfordshire, UK • Animal Health CDMO • Veterinary Specials Manufacturer • $3 Billion Global CDMO Market • >$1 Billion EU Compounding Market As a Contract Development and Manufacturing As a Compounded Veterinary Specials company, Organization (CDMO) working exclusi
Slide 14: Pharma Segment Growth
Pharma Segment Growth non-currency adjusted
Slide 15: Swedencare Group Soft Chew Applications
Swedencare Group Soft Chew Applications The globally patented Vetio soft chew matrix is a highly stable and palatable delivery system consisting of one or more pharmaceutical grade APIs or supplement ingredients. Vetio’s process & composition chew patent is the result of a decade of development.
Slide 16: Summit Vet Soft Chew Launch
Summit Vet Soft Chew Launch • Beginning in late 2025, Summit invested in a new production suite and for the development of compounded soft chew specials • Summit recently launched its first products, which have been well received by veterinarians and pet patents • As unmet needs continue to persist
Slide 17: Vetio South Expansion
Vetio South Expansion • Vetio South began another expansion earlier this year into two new categories – pet treats and Rx Non-sterile liquids. • The treats plant comes on-line in December of this year, and ramps up in Q1 2027, while the Non-Sterile Liquids operation follows later in the year. Once c
Slide 18: Vetio South Capabilities Post-Expansion
Vetio South Capabilities Post-Expansion OTC & Rx Topicals Liquids Supplements Functional Treats $3B Global Market: $5B Global Market $4B Global Market - $1B: OTC topical dermatology - Soft chews - Injection Molded and grooming products; Oral Care liquids - Tablets - Extruded - $2B: Rx Pharma Non-Ste
Slide 19: Thank you for participating!
Thank you for participating! Q&A